The prognostic molecular markers in hepatocellular carcinoma.
PDF (106K)
Journal: 2002/August - World Journal of Gastroenterology
ISSN: 1007-9327
PUBMED: 12046056
Abstract:
The prognosis of hepatocellular carcinoma (HCC) still remains dismal, although many advances in its clinical study have been made. It is important for tumor control to identify the factors that predispose patients to death. With new discoveries in cancer biology, the pathological and biological prognostic factors of HCC have been studied quite extensively. Analyzing molecular markers (biomarkers) with prognostic significance is a complementary method. A large number of molecular factors have been shown to associate with the invasiveness of HCC, and have potential prognostic significance. One important aspect is the analysis of molecular markers for the cellular malignancy phenotype. These include alterations in DNA ploidy, cellular proliferation markers (PCNA, Ki-67, Mcm2, MIB1, MIA, and CSE1L/CAS protein), nuclear morphology, the p53 gene and its related molecule MD M2, other cell cycle regulators (cyclin A, cyclin D, cyclin E, cdc2, p27, p73), oncogenes and their receptors (such as ras, c-myc, c-fms, HGF, c-met, and erb-B receptor family members), apoptosis related factors (Fas and FasL), as well as telomerase activity. Another important aspect is the analysis of molecular markers involved in the process of cancer invasion and metastasis. Adhesion molecules (E-cadherin, catenins, serum intercellular adhesion molecule-1, CD44 variants), proteinases involved in the degradation of extracellular matrix (MMP-2, MMP-9, uPA, uPAR, PAI), as well as other molecules have been regarded as biomarkers for the malignant phenotype of HCC, and are related to prognosis and therapeutic outcomes. Tumor angiogenesis is critical to both the growth and metastasis of cancers including HCC, and has drawn much attention in recent years. Many angiogenesis-related markers, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived endothelial cell growth factor (PD-ECGF), thrombospondin (TSP), angiogenin, pleiotrophin, and endostatin (ES) levels, as well as intratumor microvessel density (MVD) have been evaluated and found to be of prognostic significance. Body fluid (particularly blood and urinary) testing for biomarkers is easily accessible and useful in clinical patients. The prognostic significance of circulating DNA in plasma or serum, and its genetic alterations in HCC are other important trends. More attention should be paid to these two areas in future. As the progress of the human genome project advances, so does a clearer understanding of tumor biology, and more and more new prognostic markers with high sensitivity and specificity will be found and used in clinical assays. However, the combination of some items, i.e., the pathological features and some biomarkers mentioned above, seems to be more practical for now.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(107)
References
(115)
Diseases
(2)
Conditions
(1)
Chemicals
(4)
Organisms
(1)
Processes
(5)
Anatomy
(2)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
World J Gastroenterol 8(3): 385-392
PMID: 12046056

The prognostic molecular markers in hepatocellular carcinoma

Lun-Xiu Qin, Zhao-You Tang, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China
Author contributions: All authors contributed equally to the work.

Correspondence to: Zhao-You Tang, MD, Professor of Surgery and Chairman, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China. nc.hs.cts.pacrs@gnatyz

Telephone: +86-21-64037181 Fax: +86-21-64037181

Lun-Xiu Qin, Zhao-You Tang, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China
Author contributions: All authors contributed equally to the work.

Correspondence to: Zhao-You Tang, MD, Professor of Surgery and Chairman, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China. nc.hs.cts.pacrs@gnatyz

Telephone: +86-21-64037181 Fax: +86-21-64037181

Received 2002 Mar 19; Revised 2002 Apr 23; Accepted 2002 May 8.
Copyright ©The Author(s) 2002. Published by Baishideng Publishing Group Inc. All rights reserved.

Abstract

The prognosis of hepatocellular carcinoma (HCC) still remains dismal, although many advances in its clinical study have been made. It is important for tumor control to identify the factors that predispose patients to death. With new discoveries in cancer biology, the pathological and biological prognostic factors of HCC have been studied quite extensively. Analyzing molecular markers (biomarkers) with prognostic significance is a complementary method. A large number of molecular factors have been shown to associate with the invasiveness of HCC, and have potential prognostic significance. One important aspect is the analysis of molecular markers for the cellular malignancy phenotype. These include alterations in DNA ploidy, cellular proliferation markers (PCNA, Ki-67, Mcm2, MIB1, MIA, and CSE1L/CAS protein), nuclear morphology, the p53 gene and its related molecule MDM2, other cell cycle regulators (cyclin A, cyclin D, cyclin E, cdc2, p27, p73), oncogenes and their receptors (such as ras, c-myc, c-fms, HGF, c-met, and erb-B receptor family members), apoptosis related factors (Fas and FasL), as well as telomerase activity. Another important aspect is the analysis of molecular markers involved in the process of cancer invasion and metastasis. Adhesion molecules (E-cadherin, catenins, serum intercellular adhesion molecule-1, CD44 variants), proteinases involved in the degradation of extracellular matrix (MMP-2, MMP-9, uPA, uPAR, PAI), as well as other molecules have been regarded as biomarkers for the malignant phenotype of HCC, and are related to prognosis and therapeutic outcomes. Tumor angiogenesis is critical to both the growth and metastasis of cancers including HCC, and has drawn much attention in recent years. Many angiogenesis-related markers, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived endothelial cell growth factor (PD-ECGF), thrombospondin (TSP), angiogenin, pleiotrophin, and endostatin (ES) levels, as well as inratumor microvessel density (MVD) have been evaluated and found to be of prognostic significance. Body fluid (particularly blood and urinary) testing for biomarkers is easily accessible and useful in clinical patients. The prognostic significance of circulating DNA in plasma or serum, and its genetic alterations in HCC are other important trends. More attention should be paid to these two areas in future. As the progress of the human genome project advances, so does a clearer understanding of tumor biology, and mo re and more new prognostic markers with high sensitivity and specificity will be found and used in clinical assays. However, the combination of some items, i.e., the pathological features and some biomarkers mentioned above, seems to be more practical for now.

Abstract

Footnotes

Edited by Pagliarini R

Footnotes

References

  • 1. Tang ZYHepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol. 2001;7:445–454.[Google Scholar]
  • 2. Qin LX, Tang ZYThe prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol. 2002;8:193–199.[Google Scholar]
  • 3. Zhao WH, Ma ZM, Zhou XR, Feng YZ, Fang BSPrediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol. 2002;8:237–242.[Google Scholar]
  • 4. Zheng N, Ye SL, Sun RX, Zhao Y, Tang ZYEffects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma. World J Gastroenterol. 2002;8:233–236.[Google Scholar]
  • 5. Korn WMMoving toward an understanding of the metastatic process in hepatocellular carcinoma. World J Gastroenterol. 2001;7:777–778.[Google Scholar]
  • 6. Mise K, Tashiro S, Yogita S, Wada D, Harada M, Fukuda Y, Miyake H, Isikawa M, Izumi K, Sano NAssessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. Clin Cancer Res. 1998;4:1475–1482.[PubMed][Google Scholar]
  • 7. Nolte M, Werner M, Nasarek A, Bektas H, von Wasielewski R, Klempnauer J, Georgii AExpression of proliferation associated antigens and detection of numerical chromosome aberrations in primary human liver tumours: relevance to tumour characteristics and prognosis. J Clin Pathol. 1998;51:47–51.[Google Scholar]
  • 8. Weber JC, Nakano H, Bachellier P, Oussoultzoglou E, Inoue K, Shimura H, Wolf P, Chenard-Neu MP, Jaeck DIs a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg. 2001;182:81–88.[PubMed][Google Scholar]
  • 9. Lin GY, Chen ZL, Lu CM, Li Y, Ping XJ, Huang RImmunohistochemical study on p53, H-rasp21, c-erbB-2 protein and PCNA expression in HCC tissues of Han and minority ethnic patients. World J Gastroenterol. 2000;6:234–238.[Google Scholar]
  • 10. Scholzen T, Gerdes JThe Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–322.[PubMed][Google Scholar]
  • 11. Hernández-Rodríguez NA, Correa E, Sotelo R, Contreras-Paredes A, Gomez-Ruiz C, Green L, Mohar AKi-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma. Cancer Detect Prev. 2001;25:210–215.[PubMed][Google Scholar]
  • 12. Ito Y, Matsuura N, Sakon M, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, et al Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer. 1999;81:747–751.[Google Scholar]
  • 13. Ouchi K, Sugawara T, Ono H, Fujiya T, Kamiyama Y, Kakugawa Y, Mikuni J, Yamanami H, Komatsu S, Horikoshi AMitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma. Dig Surg. 2000;17:42–48.[PubMed][Google Scholar]
  • 14. Wellmann A, Flemming P, Behrens P, Wuppermann K, Lang H, Oldhafer K, Pastan I, Brinkmann UHigh expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: correlation with tumor progression. Int J Mol Med. 2001;7:489–494.[PubMed][Google Scholar]
  • 15. Ikeguchi M, Sato N, Hirooka Y, Kaibara NComputerized nuclear morphometry of hepatocellular carcinoma and its relation to proliferative activity. J Surg Oncol. 1998;68:225–230.[PubMed][Google Scholar]
  • 16. Veltri RW, Partin AW, Miller MCQuantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations. J Cell Biochem Suppl. 2000;Suppl 35:151–157.[PubMed][Google Scholar]
  • 17. Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner JTP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol. 2000;39:327–333.[PubMed][Google Scholar]
  • 18. Takahashi M, Tonoki H, Tada M, Kashiwazaki H, Furuuchi K, Hamada J, Fujioka Y, Sato Y, Takahashi H, Todo S, et al Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer. 2000;89:92–99.[PubMed][Google Scholar]
  • 19. Blaszyk H, Hartmann A, Cunningham JM, Schaid D, Wold LE, Kovach JS, Sommer SSA prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int J Cancer. 2000;89:32–38.[PubMed][Google Scholar]
  • 20. Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA, Weber TK, Driscoll DL, Anderson GR, Petrelli NJp53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer. 2000;88:1814–1819.[PubMed][Google Scholar]
  • 21. Ireland AP, Shibata DK, Chandrasoma P, Lord RV, Peters JH, DeMeester TRClinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg. 2000;231:179–187.[Google Scholar]
  • 22. Tamás L, Kraxner H, Mechtler L, Répássy G, Ribári O, Hirschberg A, Szentkúti G, Járay B, Szentirmay ZPrognostic significance of P53 histochemistry and DNA histogram parameters in head and neck malignancies. Anticancer Res. 2000;20:4031–4037.[PubMed][Google Scholar]
  • 23. Murakami I, Hiyama K, Ishioka S, Yamakido M, Kasagi F, Yokosaki Yp53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients. Clin Cancer Res. 2000;6:526–530.[PubMed][Google Scholar]
  • 24. Mitsudomi T, Hamajima N, Ogawa M, Takahashi TPrognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res. 2000;6:4055–4063.[PubMed][Google Scholar]
  • 25. Shahin MS, Hughes JH, Sood AK, Buller REThe prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer. 2000;89:2006–2017.[PubMed][Google Scholar]
  • 26. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindán FJ, Healey JH, Ladanyi MPrognostic impact of P53 status in Ewing sarcoma. Cancer. 2000;89:783–792.[PubMed][Google Scholar]
  • 27. Leibovich BC, Cheng L, Weaver AL, Myers RP, Bostwick DGOutcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. J Urol. 2000;163:1756–1760.[PubMed][Google Scholar]
  • 28. Osaki T, Kimura T, Tatemoto Y, Dapeng L, Yoneda K, Yamamoto TDiffuse mode of tumor cell invasion and expression of mutant p53 protein but not of p21 protein are correlated with treatment failure in oral carcinomas and their metastatic foci. Oncology. 2000;59:36–43.[PubMed][Google Scholar]
  • 29. Suzuki M, Ohwada M, Saga Y, Kohno T, Takei Y, Sato IMicrometastatic p53-positive cells in the lymph nodes of early stage epithelial ovarian cancer: prognostic significance. Oncology. 2001;60:170–175.[PubMed][Google Scholar]
  • 30. Shiota G, Ishida M, Noguchi N, Oyama K, Takano Y, Okubo M, Katayama S, Tomie Y, Harada K, Hori K, et al Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Dig Dis Sci. 2000;45:122–128.[PubMed][Google Scholar]
  • 31. Shao ZM, Wu J, Shen ZZ, Nguyen Mp53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res. 2001;7:2222–2227.[PubMed][Google Scholar]
  • 32. Kantola S, Parikka M, Jokinen K, Hyrynkangs K, Soini Y, Alho OP, Salo TPrognostic factors in tongue cancer - relative importance of demographic, clinical and histopathological factors. Br J Cancer. 2000;83:614–619.[Google Scholar]
  • 33. Ferrero JM, Ramaioli A, Formento JL, Francoual M, Etienne MC, Peyrottes I, Ettore F, Leblanc-Talent P, Namer M, Milano GP53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Ann Oncol. 2000;11:393–397.[PubMed][Google Scholar]
  • 34. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin JThe prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer. 2000;88:804–813.[PubMed][Google Scholar]
  • 35. Kaye PV, Radebold K, Isaacs S, Dent DMExpression of p53 and p21waf1/cip1 in gastric carcinoma: lack of inter-relationship or correlation with prognosis. Eur J Surg Oncol. 2000;26:39–43.[PubMed][Google Scholar]
  • 36. Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, et al Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol. 2001;19:448–457.[PubMed][Google Scholar]
  • 37. Gadducci A, Cianci C, Cosio S, Carnino F, Fanucchi A, Buttitta F, Conte PF, Genazzani ARp53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Anticancer Res. 2000;20:4793–4799.[PubMed][Google Scholar]
  • 38. Fleshner N, Kapusta L, Ezer D, Herschorn S, Klotz Lp53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol. 2000;164:1177–1182.[PubMed][Google Scholar]
  • 39. Gallego MG, Aceñero MJ, Ortega S, Delgado AA, Cantero JLPrognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum. 2000;43:971–975.[PubMed][Google Scholar]
  • 40. Nieder C, Petersen S, Petersen C, Thames HDThe challenge of p53 as prognostic and predictive factor in Hodgkin's or non-Hodgkin's lymphoma. Ann Hematol. 2001;80:2–8.[PubMed][Google Scholar]
  • 41. Itoh T, Shiro T, Seki T, Nakagawa T, Wakabayashi M, Inoue K, Okamura ARelationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J Mol Med. 2000;6:137–142.[PubMed][Google Scholar]
  • 42. Jeng KS, Sheen IS, Chen BF, Wu JYIs the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg. 2000;135:1329–1333.[PubMed][Google Scholar]
  • 43. Tang Z, Qin L, Wang X, Zhou G, Liao Y, Weng Y, Jiang X, Lin Z, Liu K, Ye SAlterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J (Engl) 1998;111:313–318.[PubMed][Google Scholar]
  • 44. Sugo H, Takamori S, Kojima K, Beppu T, Futagawa SThe significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas. Surg Today. 1999;29:849–855.[PubMed][Google Scholar]
  • 45. Heinze T, Jonas S, Kärsten A, Neuhaus PDetermination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time. Anticancer Res. 1999;19:2501–2503.[PubMed][Google Scholar]
  • 46. Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, Ji Y, Huang LW, Jia HL, Sun HC, et al P53 immunohistochemistry scoring is an independent prognostic marker of patient with hepatocellular carcinoma resection: A prospective study of 256 formalin-fixed paraffin-embedded tumor samples. World J Gastroenterol. 2002:(in press).[PubMed][Google Scholar]
  • 47. Shiota G, Kishimoto Y, Suyama A, Okubo M, Katayama S, Harada K, Ishida M, Hori K, Suou T, Kawasaki HPrognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J Hepatol. 1997;27:661–668.[PubMed][Google Scholar]
  • 48. Tangkijvanich P, Janchai A, Charuruks N, Kullavanijaya P, Theamboonlers A, Hirsch P, Poovorawan YClinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma. Asian Pac J Allergy Immunol. 2000;18:237–243.[PubMed][Google Scholar]
  • 49. Saffroy R, Lelong JC, Azoulay D, Salvucci M, Reynes M, Bismuth H, Debuire B, Lemoine AClinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer. 1999;79:604–610.[Google Scholar]
  • 50. Endo K, Ueda T, Ohta T, Terada TProtein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver. 2000;20:209–215.[PubMed][Google Scholar]
  • 51. Chao Y, Shih YL, Chiu JH, Chau GY, Lui WY, Yang WK, Lee SD, Huang TSOverexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res. 1998;58:985–990.[PubMed][Google Scholar]
  • 52. Ohashi R, Gao C, Miyazaki M, Hamazaki K, Tsuji T, Inoue Y, Uemura T, Hirai R, Shimizu N, Namba MEnhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res. 2001;21:657–662.[PubMed][Google Scholar]
  • 53. Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura NExpression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology. 2000;59:68–74.[PubMed][Google Scholar]
  • 54. Philipp-Staheli J, Payne SR, Kemp CJp27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res. 2001;264:148–168.[PubMed][Google Scholar]
  • 55. Fiorentino M, Altimari A, D'Errico A, Cukor B, Barozzi C, Loda M, Grigioni WFAcquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res. 2000;6:3966–3972.[PubMed][Google Scholar]
  • 56. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, et al Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology. 1999;30:90–99.[PubMed][Google Scholar]
  • 57. Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, Mössner J, Engeland K, Wittekind CExpression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst. 1999;91:1154–1158.[PubMed][Google Scholar]
  • 58. Qin Y, Li B, Tan YS, Sun ZL, Zuo FQ, Sun ZFPolymorphism of p16INK4a gene and rare mutation of p15INK4b gene exon2 in primary hepatocarcinoma. World J Gastroenterol. 2000;6:411–414.[Google Scholar]
  • 59. Wang Q, Lin ZY, Feng XLAlterations in metastatic properties of hepatocellular carcinoma cell following H-ras oncogene transfection. World J Gastroenterol. 2001;7:335–339.[Google Scholar]
  • 60. Cui J, Yang DH, Bi XJ, Fan ZRMethylation status of c-fms oncogene in HCC and its relationship with clinical pathology. World J Gastroenterol. 2001;7:136–139.[Google Scholar]
  • 61. Kawate S, Fukusato T, Ohwada S, Watanuki A, Morishita YAmplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology. 1999;57:157–163.[PubMed][Google Scholar]
  • 62. Tavian D, De Petro G, Benetti A, Portolani N, Giulini SM, Barlati Su-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer. 2000;87:644–649.[PubMed][Google Scholar]
  • 63. Luo YQ, Wu MC, Cong WMGene expression of hepatocyte growth factor and its receptor in HCC and nontumorous liver tissues. World J Gastroenterol. 1999;5:119–121.[Google Scholar]
  • 64. Prange W, Schirmacher PAbsence of therapeutically relevant c-erbB-2 expression in human hepatocellular carcinomas. Oncol Rep. 2001;8:727–730.[PubMed][Google Scholar]
  • 65. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, Miyoshi E, Monden M, Matsuura NExpression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84:1377–1383.[Google Scholar]
  • 66. Ito Y, Miyoshi E, Takeda T, Sakon M, Noda K, Tsujimoto M, Monden M, Taniguchi N, Matsuura NExpression and possible role of ets-1 in hepatocellular carcinoma. Am J Clin Pathol. 2000;114:719–725.[PubMed][Google Scholar]
  • 67. Ito Y, Monden M, Takeda T, Eguchi H, Umeshita K, Nagano H, Nakamori S, Dono K, Sakon M, Nakamura M, et al The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer. 2000;82:1211–1217.[Google Scholar]
  • 68. Wang XZ, Chen XC, Yang YH, Chen ZX, Huang YH, Tao QMRelationship between HBxAg and Fas/FasL in patients with hepatocellular carcinoma. World J Gas troenterol. 2000;6:S17.[PubMed][Google Scholar]
  • 69. Kobayashi T, Kubota K, Takayama T, Makuuchi MTelomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg. 2001;181:284–288.[PubMed][Google Scholar]
  • 70. Tatsuma T, Goto S, Kitano S, Lin YC, Lee CM, Chen CLTelomerase activity in peripheral blood for diagnosis of hepatoma. J Gastroenterol Hepatol. 2000;15:1064–1070.[PubMed][Google Scholar]
  • 71. Suda T, Isokawa O, Aoyagi Y, Nomoto M, Tsukada K, Shimizu T, Suzuki Y, Naito A, Igarashi H, Yanagi M, et al Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver. Hepatology. 1998;27:402–406.[PubMed][Google Scholar]
  • 72. Huang GT, Lee HS, Chen CH, Sheu JC, Chiou LL, Chen DSCorrelation of E-cadherin expression and recurrence of hepatocellular carcinoma. Hepatogastroenterology. 1999;46:1923–1927.[PubMed][Google Scholar]
  • 73. Endo K, Ueda T, Ueyama J, Ohta T, Terada TImmunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol. 2000;31:558–565.[PubMed][Google Scholar]
  • 74. Wong CM, Fan ST, Ng IObeta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer. 2001;92:136–145.[PubMed][Google Scholar]
  • 75. Cui J, Zhou XD, Liu YK, Tang ZY, Zile MHAbnormal beta-catenin gene expression with invasiveness of primary hepatocellular carcinoma in China. World J Gastroenterol. 2001;7:542–546.[Google Scholar]
  • 76. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SYBeta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 2000;157:763–770.[Google Scholar]
  • 77. Sun JJ, Zhou XD, Liu YK, Tang ZY, Feng JX, Zhou G, Xue Q, Chen JInvasion and metastasis of liver cancer: expression of intercellular adhesion molecule 1. J Cancer Res Clin Oncol. 1999;125:28–34.[PubMed][Google Scholar]
  • 78. Mei MH, Xu J, Shi QF, Yang JH, Chen Q, Qin LLClinical significance of serum intercellular adhesion molecule-1 detection in patients with hepatocellular carcinoma. World J Gastroenterol. 2000;6:408–410.[Google Scholar]
  • 79. Xu J, Mei MH, Zeng SE, Shi QF, Liu YM, Qin LLExpressions of ICAM-1 and its mRNA in sera and tissues of patients with hepatocellular carcinoma. World J Gastroenterol. 2001;7:120–125.[Google Scholar]
  • 80. Goodison S, Urquidi V, Tarin DCD44 cell adhesion molecules. Mol Pathol. 1999;52:189–196.[Google Scholar]
  • 81. Endo K, Terada TProtein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol. 2000;32:78–84.[PubMed][Google Scholar]
  • 82. Sakamoto Y, Mafune K, Mori M, Shiraishi T, Imamura H, Mori M, Takayama T, Makuuchi MOverexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. Int J Oncol. 2000;17:237–243.[PubMed][Google Scholar]
  • 83. Jiang YF, Yang ZH, Hu JQRecurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol. 2000;6:61–65.[Google Scholar]
  • 84. Bu W, Tang ZY, Ye SL, Liu KD, Huang XW, Gao DMThe association of type IV collagenase with invasion and metasta-sis of hepatocellular carcinoma. Zhonghua Xiaohua Zazhi. 1999;19:13–15.[PubMed][Google Scholar]
  • 85. Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris ALPlasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. J Pathol. 2001;195:236–243.[PubMed][Google Scholar]
  • 86. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HBInvasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol. 2000;126:641–646.[PubMed][Google Scholar]
  • 87. Itoh T, Hayashi Y, Kanamaru T, Morita Y, Suzuki S, Wang W, Zhou L, Rui JA, Yamamoto M, Kuroda Y, et al Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol. 2000;15:422–430.[PubMed][Google Scholar]
  • 88. Kuroi K, Toi MCirculating angiogenesis regulators in cancer patients. Int J Biol Markers. 2001;16:5–26.[PubMed][Google Scholar]
  • 89. Morinaga S, Imada T, Shimizu A, Akaike M, Sugimasa Y, Takemiya S, Takanashi YAngiogenesis in hepatocellular carcinoma as evaluated by alpha smooth muscle actin immunohistochemistry. Hepatogastroenterology. 2001;48:224–228.[PubMed][Google Scholar]
  • 90. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, Nabika T, Nagasue NClinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology. 1998;27:1554–1562.[PubMed][Google Scholar]
  • 91. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZCMicrovessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol. 1999;125:419–426.[PubMed][Google Scholar]
  • 92. Poon RT, Fan ST, Wong JClinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19:1207–1225.[PubMed][Google Scholar]
  • 93. Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong JSerum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg. 2001;233:227–235.[Google Scholar]
  • 94. Li XM, Tang ZY, Qin LX, Zhou J, Sun HCSerum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 1999;18:511–517.[PubMed][Google Scholar]
  • 95. Niu Q, Tang ZY, Ma ZC, Qin LX, Zhang LHSerum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol. 2000;6:565–568.[Google Scholar]
  • 96. Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, Liu F, Sun HC, Ye SLExpression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol. 2000;126:57–61.[PubMed][Google Scholar]
  • 97. Tada K, Shiraishi S, Kamiryo T, Nakamura H, Hirano H, Kuratsu J, Kochi M, Saya H, Ushio YAnalysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg. 2001;95:651–659.[PubMed][Google Scholar]
  • 98. Bisgaard ML, Jäger AC, Dalgaard P, Søndergaard JO, Rehfeld JF, Nielsen FCAllelic loss of chromosome 2p21-16.3 is associated with reduced survival in sporadic colorectal cancer. Scand J Gastroenterol. 2001;36:405–409.[PubMed][Google Scholar]
  • 99. Hirano A, Emi M, Tsuneizumi M, Utada Y, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Haga S, Kajiwara T, et al Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res. 2001;7:876–882.[PubMed][Google Scholar]
  • 100. Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet YChromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene. 2000;19:6317–6323.[PubMed][Google Scholar]
  • 101. Washburn JG, Wojno KJ, Dey J, Powell IJ, Macoska JA8pter-p23 deletion is associated with racial differences in prostate cancer outcome. Clin Cancer Res. 2000;6:4647–4652.[PubMed][Google Scholar]
  • 102. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, Sheng Z, Lau JW, Johnson PJAssessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol. 1999;154:37–43.[Google Scholar]
  • 103. Itano O, Ueda M, Kikuchi K, Shimazu M, Kitagawa Y, Aiura K, Kitajima MA new predictive factor for hepatocellular carcinoma based on two-dimensional electrophoresis of genomic DNA. Oncogene. 2000;19:1676–1683.[PubMed][Google Scholar]
  • 104. Qin LX, Tang ZY, Sham JS, Ma ZC, Ye SL, Zhou XD, Wu ZQ, Trent JM, Guan XYThe association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma. Cancer Res. 1999;59:5662–5665.[PubMed][Google Scholar]
  • 105. Qin LX, Tang ZY, Ye SL, Liu YK, Ma ZC, Zhou XD, Wu ZQ, Lin ZY, Sun FX, Tian J, et al Chromosome 8p deletion is associated with metastasis of human hepatocellular carcinoma when high and low metastatic models are compared. J Cancer Res Clin Oncol. 2001;127:482–488.[PubMed][Google Scholar]
  • 106. Zhang LH, Qin LX, Ma ZC, Ye SL, Liu YK, Ye QH, Wu X, Huang W, Tang ZYAllelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis. J Cancer Res Clin Oncol. 2003;129:279–286.[PubMed][Google Scholar]
  • 107. Anker P, Stroun MCirculating DNA in plasma or serum. Medicina (B Aires) 2000;60:699–702.[PubMed][Google Scholar]
  • 108. Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, Hoon DSPrognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res. 2001;61:5723–5726.[PubMed][Google Scholar]
  • 109. Nunes DN, Kowalski LP, Simpson AJCirculating tumor-derived DNA may permit the early diagnosis of head and neck squamous cell carcinomas. Int J Cancer. 2001;92:214–219.[PubMed][Google Scholar]
  • 110. Kennedy SProteomic profiling from human samples: the body fluid alternative. Toxicol Lett. 2001;120:379–384.[PubMed][Google Scholar]
  • 111. Tsai JF, Chuang LY, Jeng JE, Yang ML, Chang WY, Hsieh MY, Lin ZY, Tsai JHClinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma. Medicine (Baltimore) 1997;76:213–226.[PubMed][Google Scholar]
  • 112. King KL, Li AF, Chau GY, Chi CW, Wu CW, Huang CL, Lui WYPrognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer. 2000;88:2464–2470.[PubMed][Google Scholar]
  • 113. Osada T, Nagashima I, Tsuno NH, Kitayama J, Nagawa HPrognostic significance of glutamine synthetase expression in unifocal advanced hepatocellular carcinoma. J Hepatol. 2000;33:247–253.[PubMed][Google Scholar]
  • 114. Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, et al Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res. 1999;5:4005–4012.[PubMed][Google Scholar]
  • 115. Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, King KL, Loong CC, Hsia CY, Chi CWSerum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg. 2000;231:552–558.[Google Scholar]
  • 116. Pirisi M, Toniutto P, Uzzau A, Fabris C, Avellini C, Scott C, Apollonio L, Beltrami CA, Bresadola FCarriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients. Cancer. 2000;89:297–302.[PubMed][Google Scholar]
  • 117. Yamamoto Y, Sakamoto M, Fujii G, Kanetaka K, Asaka M, Hirohashi SCloning and characterization of a novel gene, DRH1, down-regulated in advanced human hepatocellular carcinoma. Clin Cancer Res. 2001;7:297–303.[PubMed][Google Scholar]
  • 118. Furumoto K, Arii S, Mori A, Furuyama H, Gorrin Rivas MJ, Nakao T, Isobe N, Murata T, Takahashi C, Noda M, et al. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs. Hepatology. 2001;33:189–195.[PubMed]
  • 119. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Robles A, C hen YD, Ma ZC, et al Gene expression profiling and supervised machine learning to define metastasis-related genes in human he patocellular carcinoma. Nature Med. 2002:(submitted).[PubMed][Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.